FDA-approved2,3Evidence: Limited human dataHormones · Sexual and reproductive health

Gonadorelin1,2

Also called Factrel, Lutrepulse, Gonadorelin acetate, Gonadorelin hydrochloride1,2,3

Key takeaway

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), the ten-amino-acid hormone that FDA’s substance registry also records as luteinizing hormone-releasing hormone.1 FDA approved two gonadorelin drugs, Factrel in 1982 and Lutrepulse in 1989, but Drugs@FDA lists every product under both applications as discontinued.2,3 In a 1990 multicenter study of 109 women with hypothalamic amenorrhea, Lutrepulse led to ovulation in more than 90%. Gonadorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.4,7

Gonadorelin at a glance

What it isA synthetic decapeptide identical to gonadotropin-releasing hormone (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), according to FDA’s substance registry.1
FDA statusFDA-approved, but discontinued. Drugs@FDA lists Factrel, NDA 018123, approved September 30, 1982, and Lutrepulse, NDA 019687, approved October 10, 1989, and lists all of their products as discontinued.2,3
Human evidenceA 1990 multicenter study of Lutrepulse in 109 women with hypothalamic amenorrhea, without a comparison group.4
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is gonadorelin?

Gonadorelin is a synthetic peptide of ten amino acids with the same sequence as natural gonadotropin-releasing hormone. FDA’s substance registry also records it as luteinizing hormone-releasing hormone and as its acetate and hydrochloride salts.1

In the United States it was the active ingredient of Factrel, as gonadorelin hydrochloride, and of Lutrepulse, as gonadorelin acetate, according to Drugs@FDA.2,3

How does gonadorelin work?

FDA’s substance registry records gonadorelin as an agonist of the gonadotropin-releasing hormone receptor.1

Lutrepulse was meant to restore normal ovulation in women whose own release of this hormone is reduced or absent, according to the 1990 study.4

What do human studies show?

In a 1990 multicenter study, 109 women with primary or secondary hypothalamic amenorrhea received Lutrepulse; 91% and 96% of them ovulated. Of pregnancies, 12% were multiple, and one woman who also took clomiphene had ovarian hyperstimulation.4

The authors judged it at least comparable in effectiveness to human menopausal gonadotropins, with lower overall risk, but the study had no randomized comparison group.4

What the evidence base contains

  • Small, short, or incompletely reported human study A multicenter study of gonadorelin acetate (Lutrepulse) in 109 women with primary or secondary hypothalamic amenorrhea, in which 91% and 96% ovulated; 12% of pregnancies were multiple.4

Evidence-strength label: Limited human data. How this label is assigned

Is gonadorelin FDA-approved?

Yes, but Drugs@FDA lists the products under both of its applications as discontinued: Factrel (gonadorelin hydrochloride), NDA 018123, with an original approval date of September 30, 1982, and Lutrepulse (gonadorelin acetate), NDA 019687, with an original approval date of October 10, 1989.2,3

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list gonadorelin.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Gonadorelin is not among them.6,7

Timeline

  1. FDA approves Factrel (gonadorelin hydrochloride), NDA 018123, according to Drugs@FDA.2
  2. FDA approves Lutrepulse (gonadorelin acetate), NDA 019687, according to Drugs@FDA.3
  3. A multicenter study of Lutrepulse in 109 women with hypothalamic amenorrhea is published.4

What is still unknown?

Why the products were discontinued: Drugs@FDA lists their status but the records reviewed here give no reason.2,3

How it compares with other fertility treatments in randomized trials, which the 1990 study did not run.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Gonadorelin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Gonadorelin are a bounded selection, not every registration or paper about Gonadorelin. For the years before Gonadorelin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Gonadorelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Gonadorelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Factrel and Lutrepulse; discontinued. A 1990 multicenter study of Lutrepulse in 109 women with hypothalamic amenorrhea reported ovulation in more than 90%. Gonadorelin is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Gonadorelin?

FDA-approved as Factrel and Lutrepulse; discontinued. A 1990 multicenter study of Lutrepulse in 109 women with hypothalamic amenorrhea reported ovulation in more than 90%. Gonadorelin is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
13
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Gonadorelin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

22Selected dated records
29Connected citations
13Populated source years1982–2026
3/4Record lanes present

Registered human studies

Trial composition

5 of 5 selected trial records include at least one phase value; 5 of 5 include a status value in the retained structured contract.

PhasesPhase 1 2Phase 2 2Phase 3 2Not applicable 1
Status at observationCompleted 4Active, not recruiting 1

PubMed bibliography

Publication composition

16 of 16 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 14Comparative Study 3Case Reports 2English Abstract 2Letter 2Research Support, Non-U.S. Gov't 2Clinical Trial 1Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
22

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 22 dated records

Research hub

Explore the Gonadorelin evidence record

Open all 22 records →
22Dated records
3Evidence types
22Cited public sources
13Source years

Change ledger

Recently changed for Gonadorelin

Open all 22 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00000325

PeptideScanner retained ClinicalTrials.gov record NCT00000325 at 2026-11-16T17:31:07.936Z. Its registry update date was 2017-01-12, and PeptideScanner's reviewed identity mapping was gonadorelin.

PeptideScanner change date
November 16, 2026
Cited source date
January 12, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00296465

PeptideScanner retained ClinicalTrials.gov record NCT00296465 at 2026-11-16T17:31:07.936Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was gonadorelin.

PeptideScanner change date
November 16, 2026
Cited source date
May 19, 2011
Evidence lane
Clinical trials

Official-source collections

Source records for Gonadorelin

Open the full research atlas →
PubMed16

16 with attributed title, venue, publication-date, and type metadata.

  1. Advances and perspectives in the analytical technology for small peptide hormones analysis: A glimpse to gonadorelin.Journal of pharmaceutical and biomedical analysis · 2023 02 23
  2. Spray congealed solid lipid microparticles as a sustained release delivery system for Gonadorelin [6-D-Phe]: Production, optimization and in vitro release behavior.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2020 06 27
  3. Reproductive performance of goats treated with free gonadorelin or nanoconjugated gonadorelin at estrus.Domestic animal endocrinology · 2019 09 06
Explore all selected literature →
ClinicalTrials.gov5

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT04037254Registry update July 10, 2026 · completed at observation
  2. NCT02653092Registry update March 2, 2026 · current at observation
  3. NCT01976728Registry update March 3, 2021 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span September 30, 1982 to July 10, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,3
  • U.S. Department of Health and Human Services6
Dated updates connected to this profile · 22

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT04037254↗

    PeptideScanner retained ClinicalTrials.gov record NCT04037254 at 2026-11-16T17:31:07.936Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was gonadorelin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02653092↗

    PeptideScanner retained ClinicalTrials.gov record NCT02653092 at 2026-11-16T17:31:07.936Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was gonadorelin.↗

  3. Literature metadata

    Advances and perspectives in the analytical technology for small peptide hormones analysis: A glimpse to gonadorelin.↗

    PubMed lists PMID 36858006 in Journal of pharmaceutical and biomedical analysis as Case Reports, Journal Article, Review, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Spray congealed solid lipid microparticles as a sustained release delivery system for Gonadorelin [6-D-Phe]: Production, optimization and in vitro release behavior.↗

    PubMed lists PMID 32599272 in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V as Journal Article, with publication-date metadata of 2020-06-27 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT01976728↗

    PeptideScanner retained ClinicalTrials.gov record NCT01976728 at 2026-11-16T17:31:07.936Z. Its registry update date was 2021-03-03, and PeptideScanner's reviewed identity mapping was gonadorelin.↗

  6. Literature metadata

    Reproductive performance of goats treated with free gonadorelin or nanoconjugated gonadorelin at estrus.↗

    PubMed lists PMID 31731249 in Domestic animal endocrinology as Journal Article, with publication-date metadata of 2019-09-06 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Biological assay of luteinizing hormone-releasing hormone (gonadorelin).↗

    PubMed lists PMID 6353073 in Journal of pharmacological methods as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1983-06 (month precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Zn2+-triggered self-assembly of Gonadorelin [6-D-Phe] to produce nanostructures and fibrils.↗

    PubMed lists PMID 30050082 in Scientific reports as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-07-26 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    The International Reference Preparation of Gonadorelin for Bioassay: a comparison with different preparations of synthetic luteinizing hormone releasing hormone using physicochemical methods of analy…↗

    PubMed lists PMID 6752326 in The Journal of endocrinology as Comparative Study, Journal Article, with publication-date metadata of 1982-10 (month precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Identification of gonadorelin (LHRH) derivatives: comparison of reversed-phase high-performance liquid chromatography and micellar electrokinetic chromatography.↗

    PubMed lists PMID 8491839 in Journal of chromatography as Comparative Study, Journal Article, with publication-date metadata of 1993-04-23 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT00000325↗

    PeptideScanner retained ClinicalTrials.gov record NCT00000325 at 2026-11-16T17:31:07.936Z. Its registry update date was 2017-01-12, and PeptideScanner's reviewed identity mapping was gonadorelin.↗

  12. Literature metadata

    [Post-traumatic panhypopituitarism. Contribution of the gonadorelin pump to the topographic diagnosis].↗

    PubMed lists PMID 2940565 in Presse medicale (Paris, France : 1983) as Case Reports, Letter, with publication-date metadata of 1986-05-10 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Gonadorelin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    Drugs@FDA: FACTREL (gonadorelin hydrochloride), NDA 018123 · original approval September 30, 1982 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  3. 3
    Drugs@FDA: LUTREPULSE KIT (gonadorelin acetate), NDA 019687 · original approval October 10, 1989 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  4. 4
    Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection (1990) · PMID 2122733 ↗

    American Journal of Obstetrics and Gynecology · Official source · Source checked November 16, 2026

  5. 5
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026